(Q39644498)

13 September 2017

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells (English)

1 reference

13 September 2017

11

Keith Flaherty

1 reference

13 September 2017

13

Dirk Schadendorf

1 reference

13 September 2017

Mario Mauthe

9

0 references

Dagmar Kulms

17

object named as

Dagmar Kulms

1 reference

13 September 2017

16

Claus Garbe

1 reference

13 September 2017

1

Heike Niessner

1 reference

13 September 2017

6

Jeannette Gogel

1 reference

13 September 2017

3

Tobias Sinnberg

1 reference

13 September 2017

5

Evelyn Maczey

1 reference

13 September 2017

18

Friedegund Meier

1 reference

13 September 2017

Daniela Beck

2

1 reference

13 September 2017

Konstantinos Lasithiotakis

4

1 reference

13 September 2017

Sascha Venturelli

7

1 reference

13 September 2017

Alexander Berger

8

1 reference

13 September 2017

Mahmoud Toulany

10

1 reference

13 September 2017

Martin Schaller

12

1 reference

13 September 2017

Tassula Proikas-Cezanne

14

1 reference

13 September 2017

Birgit Schittek

15

1 reference

13 September 2017

language of work or name

English

0 references

publication date

14 October 2010

1 reference

Journal of Investigative Dermatology

13 September 2017

1 reference

13 September 2017

131

1 reference

13 September 2017

468-479

1 reference

13 September 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1038/jid.2010.297

13 September 2017

0 references

cites work

Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Mutations of the BRAF gene in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Chemotherapy and targeted therapy combinations in advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Apoptosis and melanoma: how new insights are effecting the development of new therapies for melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

B-RAF is a therapeutic target in melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

The evolutionarily conserved TSC/Rheb pathway activates Notch in tuberous sclerosis complex and Drosophila external sensory organ development

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Growth and phenotypic characteristics of human nevus cells in culture

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Tumorigenic activity and therapeutic inhibition of Rheb GTPase

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Human melanoma progression in skin reconstructs : biological significance of bFGF.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

mTORC1 promotes survival through translational control of Mcl-1.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Opinion: Searching for the elusive targets of farnesyltransferase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Phosphatase of regenerating liver-3 localizes to cyto-membrane and is required for B16F1 melanoma cell metastasis in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Stimulated PI3K-AKT signaling mediated through ligand or radiation-induced EGFR depends indirectly, but not directly, on constitutive K-Ras activity.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

A novel BH3 mimetic reveals a mitogen-activated protein kinase-dependent mechanism of melanoma cell death controlled by p53 and reactive oxygen species.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Dynamic monitoring of cytotoxicity on microelectronic sensors

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

A fluorometric rapid microassay to identify anti-proliferative compounds for human melanoma cells in vitro

1 reference

https://api.crossref.org/works/10.1038%2FJID.2010.297

7 January 2021

Identifiers

DOI

10.1038/JID.2010.297

1 reference

13 September 2017

1 reference